All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My AML Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View AML content recommended for you

#ASCO22

Share:

Jun 3, 2022

X post image

21 Jan 2023

In case you missed it:
Take a look at the latest data from the IDHENTIFY trial, presented at #ASCO22, demonstrating the effect of enasidenib on overall survival in patients with late-stage R/R #AML and IDH2R140 or IDH2R172 mutations 👇 https://t.co/CKKEa735uH.
#leusm #leukemia

X post image

11 Aug 2022

📊 Read our summary of the pre-MEASURE study presented by @DrChrisHourigan at #ASCO22. So far, this is the largest dataset used for NGS-MRD testing, validating its use prior to allo-HSCT for adult patients in first remission

👉 https://t.co/iPJHJyCn6E 👈

#AMLsm #leusm

X post image

2 Aug 2022

👀 Take a look at the latest data from the IDHENTIFY trial, presented at #ASCO22, demonstrating the effect of enasidenib on overall survival in patients with late-stage R/R #AML and IDH2R140 or IDH2R172 mutations

👉 https://t.co/O72mqA4kwR 👈

#leusm #leukemia

X post image

13 Jul 2022

👩‍🏫 Read our roundup of the latest updates of ivosidenib in IDH1-mutated #AML from #ASCO22, including ivosidenib in combination with venetoclax ± Aza, and the molecular characterization of response in the AGILE trial

👉 https://t.co/hCFMl1sfQ6 👈

#leukemia #leusm #AMLsm

X post image

9 Jun 2022

📢For all our live congress coverage from #ASCO22 check out our twitter moment!

📚If you want to see more, visit the AML Hub for drug updates, articles and interviews with key opinion leaders!

⭐️ https://t.co/UucMeHN8GC ⭐️

#leusm #AMLsm #leukemia

https://t.co/8dxX09mYZT

X post image

7 Jun 2022

We hope you enjoyed following our live updates and congress coverage! 🎓

#ASCO22 was covered by us in Chicago, IL, as well as virtually!

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #cancerawareness

X post image

7 Jun 2022

CONGRESS #ASCO22 | Gabriel Mannis @StanfordMed considers leveraging AML genomics across the therapeutic spectrum with reference to the previous three presentations reported #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | @EuniceWangMD @RoswellPark presents the results of a phase II trial of crenolanib + 7+3 in ND FLT3 AML. (N=44) Overall CRc (CR + CRi) was 73% after 1 induction cycle; 86% after two cycles. MRD-ve CRc was achieved in 16 evaluable younger pts #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | @DrChrisHourigan @NIH discusses MRD testing prior to allo-SCT for pts with AML in first remission in the Pre-MEASURE study. (N=457). NGS-MRD prior to alloHCT in AML CR1 was prognostic. #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | Stéphane De Botton @GustaveRoussy reports on the IDHENTIFY phase III trial of pts with IDH2mut R/R AML treated with enasidenib or CCR. N=319. Median OS in the R172 subgroup was 14.6 mo with ENA vs 7.8 mo with CCR. #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | @Geoff_Uy @WUSTLmed discusses innovative treatment options for R/R #AML.

He highlights how clonal heterogeneity in AML guides resistance and relapse, and how understanding these processes can inform furfure therapy.

#leusm #leukemia #medicalcongress

X post image

7 Jun 2022

It’s the last day of @ASCO!

Don’t miss out on our final live updates!

Closing interviews, key insights, and congress coverage. 📲

Session covered 👇

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

#ASCO22 #medicalcongress #cancerawareness

X post image

7 Jun 2022

CONGRESS #ASCO22 | Andrew H. Wei @PeterMacCC discusses frontline therapy in patients fit for intensive chemotherapy. Recent developments in the area are affording increased options for fit older patients with #AML.

#leusm #cancerawareness #medicalcongress

X post image

7 Jun 2022

CONGRESS #ASCO22 | Olatoyosi Odenike, MD @UChicagoMed discusses data on intensive vs non-intensive therapy in older adults with #AML

#leusm #cancerawareness #medicalcongress

X post image

5 Jun 2022

CONGRESS #ASCO22 | James K. McCloskey MD, @JTCancerCenter describes results of treatment with CPX-351 + midostaurin in adults with newly diagnosed FLT3-mutated #AML in the V-FAST trial.

N=23
CR=82%
48% of patients proceeded to HCT

#amlsm #medicalcongress #cancerawareness

X post image

5 Jun 2022

CONGRESS #ASCO22 | @SAStricklandMD @VUMC_Cancer compares the posters by Lachowiez, De Botton & @Daver_Leukemia. He considers if oral therapy only would be possible in the future with ivo+ven alone & if adding a third agent to magrolimab+aza would improve outcomes #leusm #leukemia

X post image

5 Jun 2022

CONGRESS #ASCO22 | @Irumkhan_hem @thisisUIC considers acute #leukemia outcomes across the world. She summarizes Dr Dangudubiyyam's presentation & highlights the link between poor outcomes for treatment & low socioeconomic status not just in India but also within HICs #leusm

X post image

4 Jun 2022

CONGRESS #ASCO22 | @KyleFitzgibbon @pmcancercentre presents findings from emotion and symptom-focused engagement (EASE): A multi-site randomized control trial of an intervention for acute leukemia.

The intervention improved psychological and physical well-being of patients.

X post image

4 Jun 2022

CONGRESS #ASCO22 | @Daver_Leukemia @MDAndersonNews talks about the results of a phase Ib study of magrolimab + azacitidine in patient with TP53 mutated AML. (N = 72). CR was achieved in 33.3% of patients with half of these being MRD-ve. ORR was 48.6% #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | Stéphane De Botton @GustaveRoussy describes the molecular characterization of clinical response in patients with newly diagnosed AML with ivosidenib + azacitidine versus placebo + aza. CR + CRh: 60% ivo + aza vs 36.3% with the placebo + aza #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 |Curtis Andrew Lachowiez @MDAndersonNews reports on a phase Ib/II study of ivosidenib & venetoclax +/- aza in IDH1 mutated haem malignancies. 24 month OS for MRD -ve patients was 100%, median OS NR. MRD +ve patients had a median OS of 8 months #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | Sahitya Dangudubiyyam @aiims_newdelhi considers the challenges with treating AML in resource-constrained settings. N=316. Most important predictors of survival were baseline infection & therapy in the ward. 52% had an infection at admission #leusm #leukemia

X post image

4 Jun 2022

The @AML_Hub will be covering the following session today virtually:

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Stay tuned for live updates, key insights, and interview coverage!

#ASCO22 #medicalcongress #cancerawareness #AML #lymsm

X post image

4 Jun 2022

CONGRESS #ASCO22 | @fravandi1 of @MDAndersonNews presents results of a phase II study of ASTX727 + ventoclax in patients with R/R acute #AML or previously untreated, elderly patients unfit for chemotherapy.

The therapy was shown to be feasible and safe.

#lymsm #medicalcongress

X post image

4 Jun 2022

CONGRESS #ASCO22 | @MusaYilmazMD of @MDAndersonNews presents results of a phase I/II trial of quizartinib + decitabine + venetoclax in patients with FLT3-ITD #AML. N=28. Median follow-up was 13 months. Showed a CRc rate of 82% with median OS of 7.1 months. #leusm #medicalcongress

X post image

4 Jun 2022

CONGRESS #ASCO22 | @Geoff_Uy of @WUSTLmed presents results of an ongoing phase 1b trial of lower-intensity CPX-351 + Venetoclax in patients with newly diagnosed #AML. The combination showed promising efficacy and a tolerable safety profile.#leusm #medicalcongress #cancerawareness

X post image

4 Jun 2022

CONGRESS #ASCO22 | Harry P. Erba, MD, PhD of @DukeCancer describes eligibility for non-intensive chemotherapy randomized clinical trials in patients with newly diagnosed #AML from the Connect Myeloid Disease Registry. N=374. They found that almost 75% of patients were ineligible.

X post image

4 Jun 2022

CONGRESS #ASCO22 | @GMartinelli2 of Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST)IRCCS describes results of the Phase 1/2 DIAMOND-01 trial of SEL24/MEN1703 for patients with IDH1/2-mutated #AML. N=25. ORR=13%. Acceptable safety profile demonstrated. #leusm

X post image

31 May 2022

The @AML_Hub will be covering the 2022 ASCO Annual Meeting!

Date: 3–7 June
Location: Hybrid

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance in Chicago, IL! 🗣💻

#ASCO22 #medicalcongress #cancerawareness

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2022 American Society of Clinical Oncology

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox